PMID-33137293 – Setmelanotide Phase 3 POMC LEPR Deficiency Trials
Clement K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970.
Quick Reference
| Property | Value |
|---|---|
| PMID | 33137293 |
| DOI | 10.1016/S2213-8587(20)30364-8 |
| Year | 2020 |
| Journal | Lancet Diabetes & Endocrinology |
| Study Type | RCT (Phase 3, single-arm with placebo-controlled withdrawal) |
| Evidence Level | II |
| Sample | n=21 (10 with POMC/PCSK1 deficiency + 11 with LEPR deficiency) |
| Peptide(s) Studied | Setmelanotide |
Key Findings
- 80% of POMC/PCSK1-deficient patients achieved >=10% body weight loss at approximately 1 year (primary endpoint met)
- 45% of LEPR-deficient patients achieved >=10% body weight loss (primary endpoint met)
- Mean body weight reduction: ~25.6% in POMC/PCSK1 cohort, ~12.5% in LEPR cohort
- Hunger scores (measured by daily hunger questionnaire) decreased significantly in both cohorts
- Most common adverse events: injection site reactions (45%), skin hyperpigmentation (40%), nausea
- Hyperpigmentation is an expected on-target melanocortin effect (MC1R cross-reactivity)
- These pivotal trials led to FDA approval of setmelanotide (Imcivree) in November 2020
Study Design
Two parallel, open-label, single-arm, multicenter Phase 3 trials with a blinded placebo-controlled withdrawal period. Patients aged >=6 years with genetically confirmed POMC/PCSK1 deficiency (Trial 1) or LEPR deficiency (Trial 2) and obesity received setmelanotide 3 mg SubQ daily. An 8-week placebo-controlled withdrawal phase was included to confirm drug effect. Primary endpoint: proportion achieving >=10% weight loss after ~1 year. Secondary endpoints: hunger scores, BMI changes, waist circumference.
Limitations
- Very small sample sizes (10 and 11 patients) reflecting the rarity of these genetic conditions
- Open-label design for the main treatment period
- No long-term safety data beyond 1 year at time of publication
- Single-arm design (no parallel placebo group for the full treatment period)
- Generalizability limited to the specific rare genetic obesity syndromes studied
- Cannot extrapolate efficacy to common (polygenic) obesity
Clinical Relevance
These pivotal trials established setmelanotide as the first precision medicine for genetic obesity, demonstrating that restoring MC4R signaling downstream of defective POMC, PCSK1, or LEPR pathways can produce clinically meaningful weight loss and hunger reduction. This is a landmark in melanocortin pharmacology — while bremelanotide (PT-141) and melanotan peptides (Melanotan 1, Melanotan II) also act on melanocortin receptors, setmelanotide was specifically optimized for MC4R selectivity to target the hypothalamic appetite circuit rather than MC1R (pigmentation) or MC3R/MC5R. The approval validates the melanocortin pathway as a druggable target for obesity and provides a bridge to understanding MC4R biology relevant to other melanocortin-active peptides in the vault.
Related
#research #RCT #setmelanotide #evidence-level-II #metabolic